$695 | Single User
$1395 | Global License

Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?

Published by FirstWord Pharma: 01 Jun 2013 | 47 | In Stock

Introduction

Scope


Novartis' Gleevec is widely credited as being one of the most important drug launches of all time, having revolutionised the treatment of chronic myeloid leukaemia (CML) and transformed what was a terminal disease into a chronic one. As a result, the drug has reaped significant commercial benefits for Novartis, generating global sales of .7 billion in 2012.


However, the CML market has become increasingly crowded, following the launch of second-generation therapies – Novartis' own Tasigna and Bristol-Myers Squibb's Sprycel – and the recently launched third-generation therapy Iclusig, which is marketed by Ariad Pharmaceuticals.


Paragraph>Most usage of second- and third-generation therapies currently occurs in patients who do not gain sufficient benefit from Gleevec (which accounts for approximately 85 percent of first-line usage – which in turn accounts for around 82 percent of market share). However, some analysts and industry commentators believe that the more potent second- and third-generation products have an opportunity to be used more widely – built around a thesis that earlier use with these products produces a deeper and a faster response, which could potentially prolong overall survival (Novartis is seeking to demonstrate this benefit for Tasigna versus Gleevec).


However, there would appear to be a limited window of maximum commercial opportunity for the second- and third-generation CML therapies to displace Gleevec, given that Novartis' first-generation product will most likely face US patent expiry in 2015.


Puchase Reasons


Set against this backdrop of uncertainty, this week's Physician Views poll will ask US-based oncologists to share their opinions towards the CML treatment paradigm. Specifically the poll will ask...


  • To what extent they expect to increase their front-line usage of second- and third-generation CML therapies

  • Which of the second/third-generation therapies they perceive to have the strongest clinical profile

  • To what extent they tailor their approach to treating Gleevec-refractory patients by mutation type

  • What percentage of total CML patients they expect to treat with branded second- and third-generation therapies once generic Gleevec becomes available

  • How they expect the CML treatment paradigm to evolve post-2015
  • Table of Contents
    for Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    47 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
    ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • Allied Market Research
    • CBR Pharma
    • Current Partnering
    • Firstword
    • Global Data
    • Global Markets Direct
    • ICD Research
    • Infinti Research Technavio
    • Marketline
    • Markets and Markets
    • Micro Markets Monitor
    • MP Advisors
    • Venture Planning Group
    • GMR Data